See more : Eco World International Berhad (5283.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Carna Biosciences, Inc. (4572.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carna Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- OCL Iron and Steel Limited (OISL.NS) Income Statement Analysis – Financial Results
- Yoshicon Co.,Ltd. (5280.T) Income Statement Analysis – Financial Results
- High Wire Networks, Inc. (HWNI) Income Statement Analysis – Financial Results
- PowerSchool Holdings, Inc. (PWSC) Income Statement Analysis – Financial Results
- McLaren Technology Acquisition Corp. (MLAIU) Income Statement Analysis – Financial Results
Carna Biosciences, Inc. (4572.T)
About Carna Biosciences, Inc.
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.63B | 1.39B | 2.02B | 1.13B | 3.21B | 754.69M | 657.52M | 811.60M | 1.57B | 611.76M | 771.46M | 510.83M | 592.55M | 571.80M | 687.01M | 499.57M |
| Cost of Revenue | 175.29M | 171.55M | 135.39M | 192.15M | 207.59M | 250.70M | 222.50M | 254.43M | 269.59M | 232.96M | 232.11M | 210.37M | 202.05M | 201.83M | 215.77M | 122.99M |
| Gross Profit | 1.45B | 1.22B | 1.88B | 941.20M | 3.00B | 503.99M | 435.01M | 557.17M | 1.30B | 378.80M | 539.35M | 300.46M | 390.50M | 369.97M | 471.25M | 376.58M |
| Gross Profit Ratio | 89.22% | 87.63% | 93.29% | 83.05% | 93.53% | 66.78% | 66.16% | 68.65% | 82.82% | 61.92% | 69.91% | 58.82% | 65.90% | 64.70% | 68.59% | 75.38% |
| Research & Development | 1.90B | 1.88B | 1.84B | 1.47B | 1.28B | 1.14B | 670.86M | 513.43M | 417.25M | 561.00M | 423.00M | 376.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.00M | 0.00 | 0.00 | 62.00M | 64.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 364.72M | 0.00 | 0.00 | 346.00M | 318.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 663.72M | 602.77M | 571.42M | 523.81M | 740.08M | 507.67M | 463.21M | 467.72M | 409.58M | 416.00M | 408.00M | 382.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.49B | 2.41B | 2.00B | 2.02B | -1.19M | 4.60M | 8.92M | 30.25M | 25.73M | 25.69M | 19.08M | 59.36M | 33.63M | 967.00K | -37.35M |
| Operating Expenses | 2.57B | 2.49B | 2.41B | 2.00B | 2.02B | 1.65B | 1.13B | 981.15M | 826.83M | 1.01B | 840.05M | 758.30M | 783.74M | 768.15M | 815.52M | 672.84M |
| Cost & Expenses | 2.74B | 2.66B | 2.55B | 2.19B | 2.23B | 1.90B | 1.36B | 1.24B | 1.10B | 1.25B | 1.07B | 968.67M | 985.79M | 969.99M | 1.03B | 795.83M |
| Interest Income | 170.00K | 147.00K | 107.00K | 124.00K | 351.00K | 16.00K | 40.00K | 115.00K | 188.00K | 220.00K | 243.00K | 499.00K | 630.00K | 1.00M | 3.63M | 6.29M |
| Interest Expense | 3.45M | 5.31M | 3.93M | 7.37M | 8.16M | 10.63M | 6.90M | 5.66M | 2.29M | 2.31M | 2.12M | 2.70M | 3.36M | 2.80M | 300.00K | 128.00K |
| Depreciation & Amortization | 35.61M | 33.81M | 19.16M | 12.41M | 9.39M | 12.72M | 12.11M | 21.80M | 19.22M | 67.52M | 37.59M | 38.93M | 37.42M | 61.81M | 102.53M | 52.55M |
| EBITDA | -1.09B | -1.28B | -509.41M | -1.08B | 930.62M | -1.18B | -714.36M | -258.85M | 507.60M | -775.00M | -239.30M | -406.34M | -314.40M | -330.16M | -210.22M | -450.00M |
| EBITDA Ratio | -67.15% | -89.54% | -24.78% | -93.29% | 30.39% | -150.51% | -105.32% | -50.91% | 32.74% | -87.84% | -30.69% | -78.51% | -50.54% | -53.41% | -36.10% | -58.84% |
| Operating Income | -1.12B | -1.27B | -531.14M | -1.06B | 977.78M | -1.14B | -699.06M | -423.98M | 472.78M | -634.95M | -300.70M | -457.84M | -393.24M | -398.19M | -344.28M | -296.26M |
| Operating Income Ratio | -68.70% | -91.57% | -26.33% | -93.27% | 30.48% | -151.65% | -106.32% | -52.24% | 30.13% | -103.79% | -38.98% | -89.63% | -66.36% | -69.64% | -50.11% | -59.30% |
| Total Other Income/Expenses | -13.87M | -53.51M | -1.36M | -45.42M | -64.72M | -62.28M | -34.32M | 135.05M | 13.31M | -209.89M | 21.70M | 9.88M | 38.06M | 3.42M | 31.23M | -205.77M |
| Income Before Tax | -1.13B | -1.32B | -532.50M | -1.10B | 913.06M | -1.21B | -733.38M | -288.93M | 486.09M | -844.84M | -279.00M | -447.96M | -355.18M | -394.76M | -313.05M | -502.04M |
| Income Before Tax Ratio | -69.55% | -95.43% | -26.39% | -97.28% | 28.47% | -159.91% | -111.54% | -35.60% | 30.98% | -138.10% | -36.17% | -87.69% | -59.94% | -69.04% | -45.57% | -100.49% |
| Income Tax Expense | 22.05M | 26.14M | 1.98M | 8.55M | 84.77M | 3.77M | 3.88M | 1.01M | 29.70M | 1.88M | 3.34M | 2.03M | 6.48M | 2.34M | 2.34M | 1.00M |
| Net Income | -1.15B | -1.35B | -534.47M | -1.11B | 828.29M | -1.21B | -737.26M | -289.94M | 456.39M | -846.72M | -282.34M | -449.99M | -361.65M | -397.11M | -315.40M | -503.04M |
| Net Income Ratio | -70.91% | -97.32% | -26.49% | -98.03% | 25.82% | -160.41% | -112.13% | -35.72% | 29.08% | -138.41% | -36.60% | -88.09% | -61.03% | -69.45% | -45.91% | -100.69% |
| EPS | -68.62 | -99.10 | -42.10 | -90.33 | 76.05 | -125.02 | -78.53 | -31.64 | 52.61 | -102.18 | -36.59 | -73.28 | -61.60 | -67.64 | -58.74 | -98.14 |
| EPS Diluted | -68.62 | -99.10 | -42.10 | -90.33 | 74.51 | -125.02 | -78.53 | -31.64 | 50.05 | -102.18 | -36.59 | -73.28 | -61.60 | -67.64 | -58.74 | -98.14 |
| Weighted Avg Shares Out | 16.80M | 13.62M | 12.70M | 12.30M | 10.89M | 9.68M | 9.39M | 9.16M | 8.68M | 8.29M | 7.72M | 6.14M | 5.87M | 5.87M | 5.37M | 5.13M |
| Weighted Avg Shares Out (Dil) | 16.80M | 13.62M | 12.70M | 12.30M | 11.12M | 9.68M | 9.39M | 9.16M | 9.12M | 8.29M | 7.72M | 6.14M | 5.87M | 5.87M | 5.37M | 5.13M |
Source: https://incomestatements.info
Category: Stock Reports